Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCT810
- Development stage
- Unknown
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SCT810 is an investigational anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody developed by SinoCelltech for the treatment of moderate-to-severe hemophilia A and hemophilia B, with or without inhibitors. By targeting and blocking TFPI, SCT810 enhances the extrinsic coagulation pathway, thereby promoting hemostasis and rebalancing the coagulation cascade. This factor-independent mechanism of action bypasses the need for coagulation factors VIII or IX, offering a potentially safer, more effective, and more convenient subcutaneous prophylactic treatment option that is unaffected by the presence of inhibitors.
- Other names
- SCT810 injectionSCT-810 injectionSCT 810 injectionSCT810注射液
02
Targets
TFPI (Tissue factor pathway inhibitor)
Beyond the preview
Go deeper on SCT810.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCT810.